Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

45.85
-1.6000-3.37%
Post-market: 45.850.00000.00%19:30 EDT
Volume:748.89K
Turnover:34.79M
Market Cap:2.66B
PE:-23.95
High:47.82
Open:47.71
Low:45.79
Close:47.45
52wk High:59.68
52wk Low:42.45
Shares:58.04M
Float Shares:51.67M
Volume Ratio:1.29
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.58
PE(LYR):-67.14

Loading ...

Press Release: Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Dow Jones
·
Aug 03

Earning Preview: Supernus Pharmaceuticals Q2 revenue is expected to increase by 33.04%, and institutional views are cautiously bullish

Earnings Agent
·
Jul 29

How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Positive Earnings ESP And Renewed Beat Expectations

Simply Wall St.
·
Jul 29

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

Reuters
·
Jul 27

Supernus Pharmaceuticals to Report Q2 Results, Host Conference Call

Reuters
·
Jul 23

Supernus Pharmaceuticals (SUPN) Could Be 24% Undervalued If Its CNS Pipeline Delivers

Simply Wall St.
·
Jul 22

Supernus Pharmaceuticals (SUPN) Gets a Buy from Jefferies

TIPRANKS
·
Jul 10

Supernus Pharmaceuticals is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 09

Supernus Pharmaceuticals (SUPN) Stock Could Be 29.4% Undervalued After Strong Quarterly Results

Simply Wall St.
·
Jun 23

Definium's LSD-based depression pill delivers strong late-stage results, shares surge

Reuters
·
Jun 22

Supernus Pharmaceuticals holds annual shareholder meeting

Reuters
·
Jun 19

Relmada names ex-Sage CSO Michael Quirk senior advisor for sepranolone program

Reuters
·
Jun 11

Supernus Pharmaceuticals (SUPN) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 04

Supernus Pharmaceuticals to Participate in June Investor Conferences

GlobeNewswire
·
May 28

Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Weakness And Pipeline Progress

Simply Wall St.
·
May 26

Supernus Pharmaceuticals Inc - Under CVR Agreement, to Pay $0.50 per CVR, Totaling $33.4 Mln to Equiniti Trust Company, After Achieving Milestone 1

THOMSON REUTERS
·
May 21

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

GlobeNewswire
·
May 07

Stifel Nicolaus Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
May 06

Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
May 06

SUPN: Buy Rating Reiterated as Strong Growth Supports Unchanged $65 Price Target

TIPRANKS
·
May 06